MedTrace Logo

A Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B

NCT04112147 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-10-02

No results posted yet for this study

Summary

Primary Objective:

To evaluate the activity of Antroquinonol in patients with chronic hepatitis B

Secondary Objective:

To assess the mechanism and cytokines change of Antroquinonol in patients with chronic hepatitis B

Conditions

Interventions

DRUG

Antroquinonol capsule 100mg

Patients will receive 12-week of 50mg BID Antroquinonol

DRUG

Antroquinonol capsule 200mg

Patients will receive 12-week of 100mg BID Antroquinonol

DRUG

Placebo oral capsule

Patients will receive 12-week of 100mg BID Antroquinonol placebo

Sponsors & Collaborators

  • Golden Biotechnology Corporation

    collaborator INDUSTRY

  • Cheng-Chung Wei

    lead OTHER

Principal Investigators

  • Wei C- C, M.D. · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-10
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04112147 on ClinicalTrials.gov